Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 23c

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q2 EPS of ($0.52), $0.23 better than the analyst estimate of ($0.75).

For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.

You May Also Be Interested In

• Deutsche Bank Downgrades argenx SE (ARGX:BB) (ARGX) to Hold
• MetLife (MET) PT Raised to $106 at Evercore ISI
• Nvidia launches Groq 3 LPX inference accelerator in full production